Lilly Humatrope Postmarket Plans: Voluntary Study, No Patient Registry
An assessment of the long-term safety and efficacy of Lilly's Humatrope for idiopathic short stature will rely on a voluntary ongoing postmarket research program
An assessment of the long-term safety and efficacy of Lilly's Humatrope for idiopathic short stature will rely on a voluntary ongoing postmarket research program